Skip to content
DataLookout
Menu

IPAX BrIGHTNCT07100730

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jul 2027 to Jul 2028 Show 5 more changesShow less
    • Eligibility criteria expanded, about 29 words
    • Study completion pushed from Nov 2027 to Nov 2028
    • Enrollment target: 50 to 51
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study sites revised (9)
  2. Minor Trial sites expanded: 4 → 9 locationsv6
  3. Minor Site details revised at 1 of 4 sitesv5
  4. Minor Study sites: 3 to 4v4
  5. Minor Study sites: 2 to 3v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Sep 1, 2025 to Nov 2, 2025
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and Tolerability
Timeframe: Through study completion, an average of 2 years
Dose Optimization
Timeframe: Through study completion, an average of 2 years

Secondary (3)

TLX101-Tx Concentration in the blood
Radiation Dosimetry
TLX101-Tx Concentration in the Urine

Arms and interventions

TLX101-Tx + Standard of CareExperimental

TLX101-Tx + Lomustine

TLX101-Tx OnlyExperimental

TLX101-Tx Therapy only

Combination products: TLX-101-Tx + Lomustine

Radiation: TLX101-Tx

Sites

9 sites in 4 countries

Australia 4, Belgium 2, Netherlands 2, Austria 1